Latest Headlines
-
NAMSA Announces Strategic Acquisition Of Select Assets Of The Early Development Medical Device Testing Business Of Labcorp
1/8/2026
NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services.
-
Prolytix Expands Capabilities In Thrombosis And Hemostasis Testing
1/8/2026
Prolytix, a U.S.-based leader in bioanalytical and protein characterization services, announces it has acquired 60 validated assays previously owned by Hemostasis Reference Laboratory (HRL).
-
Inspira Outlines Strategic Vision And Transaction Framework For Breast Cancer Liquid Biopsy Expansion
1/8/2026
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company’s core respiratory and life-support technologies.
-
InterVenn Biosciences Partners With Aranscia To Accelerate Commercialization Of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test
1/7/2026
InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced a partnership where Aranscia technical and laboratory resources will help to facilitate clinical workflows and expand the availability of InterVenn's flagship GlycoKnow™ Ovarian cancer diagnostic test.
-
SOPHiA GENETICS And MD Anderson Announce Strategic Collaboration To Accelerate AI-Driven Precision Oncology
1/7/2026
SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.
-
Sectra Begins Implementation Of Its First Digital Pathology Project In Japan, Aiming To Improve Cancer Diagnostics And Decrease Time To Treatment
1/7/2026
International medical technology and cybersecurity company Sectra (STO: SECT B), in collaboration with distribution partner Matsunami Glass has commenced the implementation phase of its first digital pathology project in Japan.
-
Cardio Diagnostics, Aimil Ltd. And Dr. Lal PathLabs Limited Partner To Launch The PrecisionCHD Test In India
1/7/2026
Cardio Diagnostics Holdings, Inc. a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories and 300+ MD pathologists in their internal network, today announced a strategic agreement to launch Cardio Diagnostics’ PrecisionCHD test for the detection and management of coronary heart disease (CHD) in India.
-
altona Diagnostics Launches AltoStar HDV RT-PCR Kit 1.5 (CE-IVD)
1/6/2026
altona Diagnostics GmbH announces the launch of the AltoStar HDV RT-PCR Kit 1.5 (CE-IVD), a new PCR test for the detection and quantification of hepatitis delta virus (HDV) specific RNA in human EDTA plasma and serum.
-
PracticeQ Partners With Fullscript To Streamline Lab Testing And Improve Patient Care
1/6/2026
PracticeQ today announced the launch of its new labs on Fullscript integration, designed to give providers a seamless way to order, track, and manage lab testing directly within their clinical workflows.
-
New Handheld Decapper Boosts Speed And Consistency Of 48-Format Tube Handling.
1/5/2026
Azenta Life Sciences has launched the IntelliXcap M6 Semi-Automated Handheld Screw Cap Decapper, a new addition to its range of decapper / recapper instruments designed specifically for 48-format external thread screw cap tubes.